LabCorp 2009 Annual Report Download - page 18

Download and view the complete annual report

Please find page 18 of the 2009 LabCorp annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 66

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66

Laboratory testing is a modest
part of U.S. health care spending
but it remains a huge market –
at $55 billion and growing.
LabCorp has captured nine
percent of the total market.
Opportunities for further
growth abound: an aging pop-
ulation, advances in genomics,
a growing recognition of the
importance of screening tests
for risk factors, and the advent
of companion diagnostics are
all likely to be strong drivers
of growth for years to come.
Our nationwide infrastructure,
effi cient operations and scien-
tifi c leadership position us to
attract accounts currently
served by thousands of small
independent labs, physician’s
offi ces and hospitals. Our
leading-edge science and
cost-effective operations
position us to gain market
share in the future.
How We Deliver Results:
16 LABORATORY CORPORATION OF AMERICA
OUR
INDUSTRY
An Approximate
$55 Billion
Market
OUR
COLLABORATIVE
PARTNERSHIPS
The
Foremost
In The Industry
LabCorp has long enjoyed a
reputation as the “lab partner of
choice” for leading biotech com-
panies and academic institutions.
These partners recognize our
scientifi c capabilities, as well as
our commitment to commercial-
ize new, innovative tests that
enhance the diagnosis and
treatment of disease. Today,
we are proud to count among
our partners: ARCA biopharma
(companion diagnostics in CVD),
Celera Diagnostics (breast
cancer), Duke University
(lung cancer), Exact Sciences
(colon cancer), Intema Ltd.
(prenatal testing), Ipsogen
(molecular diagnostics),
OncoMethylome Sciences
(companion diagnostics in
oncology), Siemens Healthcare
(companion diagnostics in
oncology and CVD), SmartGene
(bioinformatics tools), Veridex
(prostate cancer) and Yale
University (ovarian cancer).